Chemotherapy-induced peripheral neuropathy: Current status and progress

• CIPN is a common toxicity of multiple chemotherapy agents.
• To date there are no reliable genomic biomarkers to predict CIPN.
• New stem-cell derived neuron models are promising to advance the field.

As there are increasing numbers of cancer survivors, more attention is being paid to the long term unwanted effects patients may experience as a result of their treatment and the impact these side effects can have on their quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxicities from chemotherapy. In this review we will briefly review the clinical presentation, evaluation and management of chemotherapy-induced peripheral neuropathy, with a focus on CIPN related to platinum and taxane agents. We will then discuss current clinical models of peripheral neuropathy and ongoing research to better understand CIPN and develop potential treatment options.